C-PBR28 and F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis
Overview
Authors
Affiliations
The objective of this study was to assess microglial activation in lesions and in normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients using PET. Thirty-four MS patients (7 with secondary progressive MS [SPMS], 27 with relapsing remitting MS [RRMS]) and 30 healthy volunteers, genetically stratified for translocator protein (TSPO) binding status, underwent PET scanning with TSPO radioligands (C-PBR28 or F-PBR111). Regional TSPO availability was measured as a distribution volume ratio (DVR) relative to the caudate (a pseudoreference region). White matter lesions (WMLs) were classified as "active" (DVR highest in the lesion), "peripherally active" (perilesional DVR highest), "inactive" (DVR highest in surrounding NAWM), or "undifferentiated" (similar DVR across lesion, perilesional and NAWM volumes). The mean DVR in NAWM of patients was greater than that of the healthy volunteer white matter for both radioligands. Uptake for individual WML in patients was heterogeneous, but the median WML DVR and NAWM DVR for individual patients were strongly correlated (ρ = 0.94, = 4 × 10). A higher proportion of lesions were inactive in patients with SPMS (35%) than RRMS (23%), but active lesions were found in all patients, including those on highly efficacious treatments. TSPO radioligand uptake was increased in the brains of MS patients relative to healthy controls with 2 TSPO radiotracers. WML showed heterogeneous patterns of uptake. Active lesions were found in patients with both RRMS and SPMS. Their independent prognostic significance needs further investigation.
Characteristics of TSPO expression in marmoset EAE.
Falk I, Maric D, Leibovitch E, Sati P, Lefeuvre J, Luciano N J Neuroinflammation. 2025; 22(1):19.
PMID: 39871344 PMC: 11773908. DOI: 10.1186/s12974-025-03343-4.
Dal-Bianco A, Oh J, Sati P, Absinta M Ther Adv Neurol Disord. 2024; 17():17562864241306684.
PMID: 39711984 PMC: 11660293. DOI: 10.1177/17562864241306684.
Treaba C, Herranz E, Barletta V, Mehndiratta A, Sloane J, Granberg T Mult Scler. 2024; 30(14):1755-1764.
PMID: 39436837 PMC: 11742271. DOI: 10.1177/13524585241284157.
Meng H, He L, Chunyu H, Zhou Q, Wang J, Qu Q J Neurol. 2024; 271(12):7592-7604.
PMID: 39294471 DOI: 10.1007/s00415-024-12690-w.
Assessing disease progression and treatment response in progressive multiple sclerosis.
Comi G, Dalla Costa G, Stankoff B, Hartung H, Soelberg Sorensen P, Vermersch P Nat Rev Neurol. 2024; 20(10):573-586.
PMID: 39251843 DOI: 10.1038/s41582-024-01006-1.